1L Pancreatic Cancer
IMRXImmuneering CorporationCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Atebimetinib (IMM-1-104) (MEK Inhibitor) in 1L Pancreatic Cancer. The expected timing is based on the latest available company guidance and may change.
05/15/26:- MAPKeeper 301 is recruiting. First patient dosing remains on track for Mid-2026. 05/21/26:- MAPKeeper 301 (NCT07562152) recruiting; first patient dosing still expected Mid-2026. 06/01/26:- MAPKeeper 301 recruiting; first patient dosing still expected Mid-2026. Topline Phase 3 readout expected Mid-2028. 06/11/26:- First patient dosed in MAPKeeper 301 Ph3. Topline OS data expected Mid-2028. 08/05/26:- MAPKeeper 301 is underway with over 30 sites posted. Topline data expected Mid-2028.
Verification
Confirm timing and program details against the company announcement or filing.